Liraglutide (1.8 mg daily) was tested in the Lira Pump trial for its safety and effectiveness as an adjuvant treatment for overweight individuals with T1D who were treated with insulin pumps and had poor glycemic control. This evidence concerns the gene INS and type 1 diabetes mellitus.